Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 219
    Published on July 30, 2017


REMOVAL trial shows heart disease risk reduction with metformin medication

A study done by researchers at the University of Glasgow, Scotland, shows long-term risk reduction for heart disease with metformin diabetes medication in middle-aged type 1 diabetes (T1D) patients who are with increased cardiovascular diseases (CVD) risk factors. In the REMOVAL trial, researchers used ultrasound to measure atherosclerosis of the carotid arteries in the neck area, which supply blood to neck, face and brain. The total number of adult participants in the REMOVAL trial were 428 with more than 40 years of age and having long-standing type 1 diabetes (T1D) complication. The participants in the trial had at least three of the following cardiovascular diseases (CVD) risk factors.


During the 3 years duration REMOVAL trial period, the participants were under either metformin or matching placebo medication. Researchers observed following in the participants during the trial.

  • Weight loss
  • Reduction in the insulin doses
  • Reduction in HbA1c levels (or sugar levels/glycemic levels GI) in the first three months of the study
  • Reduction in cholesterol levels. More than 80 percent of the participants were under statin medication before the trial itself and further reduction with metformin observed during REMOVAL trial

REMOVAL trial shows heart disease risk reduction with metformin medication.

Researchers attributed a reduction in atherosclerosis to metformin drug treatment, which reduced body weight and cholesterol levels. Researchers say REMOVAL trial shows heart disease risk reduction in type 1 diabetes (T1D) patients with the metformin medication. They also say guidelines should be updated as their study shows metformin drug reduces blood sugar or glucose levels for a very short period of time. The chief investigator of the study was Professor John Petrie, MD, PhD, at the University of Glasgow, Scotland. The study findings were presented to the American Diabetes Association during 77th Scientific Sessions, San Diego Convention Center, United States. The study findings were published June 11, 2017, in The Lancet Diabetes & Endocrinology. Title of the article was "Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomized, placebo-controlled trial".




Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic


1. Metformin Improves Health Outcomes In HER2 And Breast Cancer Patients With Diabetes
2. Improved Mortality Among Older Type 2 Diabetes Individuals With Metformin
3. Wearable Contact Lenses To Measure Blood Sugar Levels
4. Wearable Technology In Elder Care
5. About Esysta device
6. About Meizus H1 Wearable Device
7. No gender difference in stress as risk of coronary heart disease (CAD)
8. The ACALM study shows married people with heart disease risks have higher survival rates

 

 

Preeclampsia or gestational hypertension was linked to increased future heart disease risk in women


Preeclampsia gestational hypertension was linked to future heart disease risk in women.

The Heart Foundation, Australia says there is an enhanced risk of future heart diseases in those women who suffered preeclampsia or gestational hypertension during pregnancy. Ms. Julie Anne Mitchell, national spokeswoman for women's heart health of The Heart Foundation, Australia says those women should monitor their heart health after pregnancy. They call pregnancy as an "ultimate cardiac stress test". In Australia, studies show during pregnancy, around 30,000 women develop high blood pressure and 10,000 of them with preeclampsia condition. This dangerous complication forces the heart to work harder. Earlier studies show following enhanced future complications with preeclampsia or gestational hypertension.


  • A fourfold enhanced risk for the development of high blood pressure
  • Two to three times enhanced risk for the development of cardiovascular diseases



Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK to your social media is (copy and paste the code below) :

Articles similar to this topic


1. Increase In Risk For Gestational Diabetes With Increase In Outdoor Temperatures
2. Green Tea EGCG Compound Found To Improve Gestational Diabetes GD Health Outcomes
3. Risk of High blood pressure Hypertension Being Short
4. New Guidelines For Treating Hypertension
5. Aspirin may cut breast cancer risk for women with diabetes
6. Discovery Of Prkca Gene Which Causes Birth Defects And Neural Tube Defects (NTDs) In Pregnant Women With Diabetes
7. Heartisans Wearable Smartwatch Device That Can Alert Heart Attacks
8. New Diabetes Contact Wearable Lens Solves Comfort And Vision Issues

 

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.